[Practical aspects of the application of CAR T cells and management of their toxicities].

CD19 CAR T cells induce - in part long-lasting - remissions in heavily pretreated patients with relapsed/refractory B-cell malignancies. However, they are associated with unique toxicities, and patient management therefore requires specific expertise.In this review, we outline the basics of their mode of action and present the currently available data on their efficacy in various B-cell and plasma cell malignancies. Currently approved therapies (Tisagenlecleucel, Axicabtagene ciloleucel, Brexucabtagene autoleucel) for patients are outlined as well as indications where approvals are expected in the near future. We discuss practical aspects of CAR T cell therapy from the patient's initial presentation, over leukapheresis, to CAR T cell transfusion. Additionally, we highlight the pathophysiology and principles of the management of the most common toxicities (cytokine release syndrome [CRS], immune cell associated neurotoxicity syndrome [ICANS] and cytopenias).

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

Die Autoren erklären, Forschungsunterstützung von Gilead, Miltenyi Biotec, Morphosys, Roche und Seattle Genetics erhalten zu haben. Darüber hinaus waren sie in Beratungsgremien für BMS, Celgene, Gilead, Pfizer, Novartis und Roche tätig und haben Educational Grants von Novartis, Celgene und Kite Gilead erhalten.